Misoprostol

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Major congenital malformations2.86 [1.44, 5.65]0%3 studies36388not evaluable ROB5.16 [2.24; .]
All congenital malformations (majors, minors, majors and minors, or unspecified)2.64 [1.03, 6.76]-1 study86118not evaluable ROB4.72 [1.21; .]
Nervous system anomalies4.23 [1.47, 12.16]-1 study34145not evaluable ROB7.93 [2.30; .]
Limb reduction defects (LRD)15.12 [5.53, 41.34]0%2 studies6147not evaluable ROB29.74 [10.54; .]
Moebius syndrome32.19 [10.54, 98.31]0%2 studies12574not evaluable ROB63.88 [20.57; .]
Oro-facial clefts5.74 [1.34, 24.59]-1 study3452not evaluable ROB10.96 [2.01; .]
Abdominal wall defects6.36 [2.38, 16.96]-1 study3423not evaluable ROB12.20 [4.20; .]
Vascular disruption anomalie22.00 [6.59, 73.42]-1 study9344not evaluable ROB43.49 [12.66; .]
5 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preterm (< 37 weeks)3.51 [1.38, 8.91]-1 study20145not evaluable ROB6.48 [2.11; .]

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Early intrauterine death (< 22 weeks)2.16 [1.40, 3.34]36%2 studies36296not evaluable ROB3.74 [2.14; .]
Intrauterine deaths (as a whole or unspecified)2.27 [1.30, 3.97]-1 study4694not evaluable ROB3.97 [1.92; .]
Elective/induced termination of pregnancy5.33 [2.93, 9.71]-1 study74236not evaluable ROB10.14 [5.31; .]
2 non statistically significant endpoints reported in only one study